Explore the vast range of titles available.

Free-roaming dogs (Canis familiaris) are common worldwide, often maintaining diseases of domestic pets and wildlife. Management of these dogs is difficult and often involves capture, treatment, neutering and release. Information on the effects of sex and reproductive state on intraspecific contacts and disease transmission is currently lacking, but is vital to improving strategic management of their populations. We assessed the effects of sex and reproductive state on short-term activity patterns and contact rates of free-roaming dogs living in an Australian Indigenous community. Population, social group sizes and rates of contact were estimated from structured observations along walked transects. Simultaneously, GPS telemetry collars were used to track dogs' movements and to quantify the frequency of contacts between individual animals. We estimated that the community's dog population was 326 ± 52, with only 9.8 ± 2.5% confined to a house yard. Short-term activity ranges of dogs varied from 9.2 to 133.7 ha, with males ranging over significantly larger areas than females. Contacts between two or more dogs occurred frequently, with entire females and neutered males accumulating significantly more contacts than spayed females or entire males. This indicates that sex and reproductive status are potentially important to epidemiology, but the effect of these differential contact rates on disease transmission requires further investigation. The observed combination of unrestrained dogs and high contact rates suggest that contagious disease would likely spread rapidly through the population. Pro-active management of dog populations and targeted education programs could help reduce the risks associated with disease spread.

The socio-ecological roles and status of free-roaming dogs ( Canis familiaris ) in Australian urban, peri-urban and other environments are complex. We review and synthesise those complexities and identify knowledge deficits and impediments to adoption of best-practice management of free-roaming dogs. Briefly, perceptions of the roles and impacts of free-roaming dogs in Australia are affected by their status as native, introduced and culturally significant animals, the situations in which they occur and the other species, including humans, with which they interact. Their negative, neutral and positive impacts often occur contemporaneously making free-roaming dogs a ‘wicked’ problem. We propose and evaluate a One Health-based solution using an environmental psychology perspective in a strategic adaptive management framework. This includes: a typology of free-roaming dogs that assists in the situational definition of animal and public health and welfare issues; identification of some human dimensions affecting management of free-roaming dogs; identification of discipline specialities that require inclusion in an effective One Health approach; audience segmentation, and; priorities for research and policy development to encourage adoption of best-practice management for each occurrence of free-roaming dog impacts.

Dogs (Canis familiaris) can transmit pathogens to other domestic animals, humans and wildlife. Both domestic and wild-living dogs are ubiquitous within mainland Australian landscapes, but their interactions are mostly unquantified. Consequently, the probability of pathogen transfer among wild-living and domestic dogs is unknown. To address this knowledge deficit, we established 65 camera trap stations, deployed for 26,151 camera trap nights, to quantify domestic and wild-living dog activity during 2 years across eight sites in north-east New South Wales, Australia. Wild-living dogs were detected on camera traps at all sites, and domestic dogs recorded at all but one. No contacts between domestic and wild-living dogs were recorded, and limited temporal overlap in activity was observed (32 %); domestic dogs were predominantly active during the day and wild-living dogs mainly during the night. Contact rates between wild-living and between domestic dogs, respectively, varied between sites and over time (range 0.003–0.56 contacts per camera trap night). Contact among wild-living dogs occurred mainly within social groupings, and peaked when young were present. However, pup emergence occurred throughout the year within and between sites and consequently, no overall annual cycle in contact rates could be established. Due to infrequent interactions between domestic and wild-living dogs, there are likely limited opportunities for pathogen transmission that require direct contact. In contrast, extensive spatial overlap of wild and domestic dogs could facilitate the spread of pathogens that do not require direct contact, some of which may be important zoonoses.

One expected consequence of global climate change is an increased likelihood in extreme weather events, including higher amplitude temperature fluctuation. This work examined the effect of low and high amplitude temperature fluctuation on predation, foraging behaviour and longevity of Dicyphus hesperus Knight (Heteroptera: Miridae). Results indicate that temperature fluctuations do influence foraging behaviour and adult longevity but the degree to which these are influenced is affected by host plant species. The results from this work suggest that the role of temperature fluctuation should be considered in future research as constant temperature models may not be representative of what is currently occurring in nature (low amplitude fluctuations) or what may occur as a result of climate change (high amplitude fluctuations).

Previous prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy in women with suspected pre-eclampsia, but we remain uncertain of the effectiveness of these tests in a real-world setting. We therefore aimed to determine whether knowledge of the circulating concentration of placental growth factor (PlGF), an angiogenic factor, integrated with a clinical management algorithm, decreased the time for clinicians to make a diagnosis in women with suspected pre-eclampsia, and whether this approach reduced subsequent maternal or perinatal adverse outcomes. We did a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial in 11 maternity units in the UK, which were each responsible for 3000–9000 deliveries per year. Women aged 18 years and older who presented with suspected pre-eclampsia between 20 weeks and 0 days of gestation and 36 weeks and 6 days of gestation, with a live, singleton fetus were invited to participate by the clinical research team. Suspected pre-eclampsia was defined as new-onset or worsening of existing hypertension, dipstick proteinuria, epigastric or right upper-quadrant pain, headache with visual disturbances, fetal growth restriction, or abnormal maternal blood tests that were suggestive of disease (such as thrombocytopenia or hepatic or renal dysfunction). Women were approached individually, they consented for study inclusion, and they were asked to give blood samples. We randomly allocated the maternity units, representing the clusters, to blocks. Blocks represented an intervention initiation time, which occurred at equally spaced 6-week intervals throughout the trial. At the start of the trial, all units had usual care (in which PlGF measurements were also taken but were concealed from clinicians and women). At the initiation time of each successive block, a site began to use the intervention (in which the circulating PlGF measurement was revealed and a clinical management algorithm was used). Enrolment of women continued for the duration of the blocks either to concealed PlGF testing, or after implementation, to revealed PlGF testing. The primary outcome was the time from presentation with suspected pre-eclampsia to documented pre-eclampsia in women enrolled in the trial who received a diagnosis of pre-eclampsia by their treating clinicians. This trial is registered with ISRCTN, number 16842031. Between June 13, 2016, and Oct 27, 2017, we enrolled and assessed 1035 women with suspected pre-eclampsia. 12 (1%) women were found to be ineligible. Of the 1023 eligible women, 576 (56%) women were assigned to the intervention (revealed testing) group, and 447 (44%) women were assigned to receive usual care with additional concealed testing (concealed testing group). Three (1%) women in the revealed testing group were lost to follow-up, so 573 (99%) women in this group were included in the analyses. One (<1%) woman in the concealed testing group withdrew consent to follow-up data collection, so 446 (>99%) women in this group were included in the analyses. The median time to pre-eclampsia diagnosis was 4·1 days with concealed testing versus 1·9 days with revealed testing (time ratio 0·36, 95% CI 0·15–0·87; p=0·027). Maternal severe adverse outcomes were reported in 24 (5%) of 447 women in the concealed testing group versus 22 (4%) of 573 women in the revealed testing group (adjusted odds ratio 0·32, 95% CI 0·11–0·96; p=0·043), but there was no evidence of a difference in perinatal adverse outcomes (15% vs 14%, 1·45, 0·73–2·90) or gestation at delivery (36·6 weeks vs 36·8 weeks; mean difference −0·52, 95% CI −0·63 to 0·73). We found that the availability of PlGF test results substantially reduced the time to clinical confirmation of pre-eclampsia. Where PlGF was implemented, we found a lower incidence of maternal adverse outcomes, consistent with adoption of targeted, enhanced surveillance, as recommended in the clinical management algorithm for clinicians. Adoption of PlGF testing in women with suspected pre-eclampsia is supported by the results of this study. National Institute for Health Research.

This research investigates the design and implementation of elastomer-based piezoresistive strain sensors and applies them to a data glove to demonstrate their application. The piezoresistive strain sensors are made by mixing Ecoflex 00-30 and carbon-black nanoparticles and then using stencil and doctor blading to deposit the piezoresistive traces as a mass fabrication technique. The primary objective is to integrate two sensing piezoresistive elements as one single-piece sensor that detects the bending angles of the metacarpophalangeal and proximal interphalangeal joints of each finger. Using a unique zig-zag pattern allows to selectively mask any unwanted piezoresistive sensing. The sensor has a gage factor of 0.68. Experiments conducted have demonstrated that the use of these soft, flexible, and stretchable piezoresistive sensors is repeatable and viable sensors for data-glove and has the potential for other wearable applications.

Background Inherited metabolic diseases (IMDs) are a group of individually rare single-gene diseases. For many IMDs, there is a paucity of high-quality evidence that evaluates the effectiveness of clinical interventions. Clinical effectiveness trials of IMD interventions could be supported through the development of core outcome sets (COSs), a recommended minimum set of standardized, high-quality outcomes and associated outcome measurement instruments to be incorporated by all trials in an area of study. We began the process of establishing pediatric COSs for two IMDs, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU), by reviewing published literature to describe outcomes reported by authors, identify heterogeneity in outcomes across studies, and assemble a candidate list of outcomes. Methods We used a comprehensive search strategy to identify primary studies and guidelines relevant to children with MCAD deficiency and PKU, extracting study characteristics and outcome information from eligible studies including outcome measurement instruments for select outcomes. Informed by an established framework and a previously published pediatric COS, outcomes were grouped into five, mutually-exclusive, a priori core areas: growth and development, life impact, pathophysiological manifestations, resource use, and death. Results For MCAD deficiency, we identified 83 outcomes from 52 articles. The most frequently represented core area was pathophysiological manifestations, with 33 outcomes reported in 29/52 articles (56%). Death was the most frequently reported outcome. One-third of outcomes were reported by a single study. The most diversely measured outcome was cognition and intelligence/IQ for which eight unique measurement instruments were reported among 14 articles. For PKU, we identified 97 outcomes from 343 articles. The most frequently represented core area was pathophysiological manifestations with 31 outcomes reported in 281/343 articles (82%). Phenylalanine concentration was the most frequently reported outcome. Sixteen percent of outcomes were reported by a single study. Similar to MCAD deficiency, the most diversely measured PKU outcome was cognition and intelligence/IQ with 39 different instruments reported among 82 articles. Conclusions Heterogeneity of reported outcomes and outcome measurement instruments across published studies for both MCAD deficiency and PKU highlights the need for COSs for these diseases, to promote the use of meaningful outcomes and facilitate comparisons across studies.

Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia. In this multicentre, parallel-group, superiority, randomised controlled trial, done in 22 maternity units across England, Scotland, and Wales, we recruited women aged 18 years or older with suspected pre-eclampsia between 22 weeks and 0 days of gestation and 35 weeks and 6 days of gestation. Women were randomly assigned (1:1) to revealed repeat PlGF-based testing or concealed repeat testing with usual care. The intervention was not masked to women or partners, or clinicians or data collectors, due to the nature of the trial. The trial statistician was masked to intervention allocation. The primary outcome was a perinatal composite of stillbirth, early neonatal death, or neonatal unit admission. The primary analysis was by the intention-to-treat principle, with a per-protocol analysis restricted to women managed according to their allocation group. The trial was prospectively registered with the ISRCTN registry, ISRCTN 85912420. Between Dec 17, 2019, and Sept 30, 2022, 1253 pregnant women were recruited and randomly assigned treatment; one patient was excluded due to randomisation error. 625 women were allocated to revealed repeat PlGF-based testing and 627 women were allocated to usual care with concealed repeat PlGF-based testing (mean age 32·3 [SD 5·7] years; 879 [70%] white). One woman in the concealed repeat PlGF-based testing group was lost to follow-up. There was no significant difference in the primary perinatal composite outcome between the revealed repeat PlGF-based testing group (195 [31·2%]) of 625 women) compared with the concealed repeat PlGF-based testing group (174 [27·8%] of 626 women; relative risk 1·21 [95% CI 0·95–1·33]; p=0·18). The results from the per-protocol analysis were similar. There were four serious adverse events in the revealed repeat PlGF-based testing group and six in the concealed repeat PlGF-based testing group; all serious adverse events were deemed unrelated to the intervention by the site principal investigators and chief investigator. Repeat PlGF-based testing in pregnant women with suspected pre-eclampsia was not associated with improved perinatal outcomes. In a high-income setting with a low prevalence of adverse outcomes, universal, routine repeat PlGF-based testing of all individuals with suspected pre-eclampsia is not recommended. Tommy's Charity, Jon Moulton Charitable Trust, and National Institute for Health and Care Research Guy's and St Thomas' Biomedical Research Centre.

Inherited metabolic diseases (IMDs) are a group of individually rare single-gene diseases. For many IMDs, there is a paucity of high-quality evidence that evaluates the effectiveness of clinical interventions. Clinical effectiveness trials of IMD interventions could be supported through the development of core outcome sets (COSs), a recommended minimum set of standardized, high-quality outcomes and associated outcome measurement instruments to be incorporated by all trials in an area of study. We began the process of establishing pediatric COSs for two IMDs, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU), by reviewing published literature to describe outcomes reported by authors, identify heterogeneity in outcomes across studies, and assemble a candidate list of outcomes. We used a comprehensive search strategy to identify primary studies and guidelines relevant to children with MCAD deficiency and PKU, extracting study characteristics and outcome information from eligible studies including outcome measurement instruments for select outcomes. Informed by an established framework and a previously published pediatric COS, outcomes were grouped into five, mutually-exclusive, a priori core areas: growth and development, life impact, pathophysiological manifestations, resource use, and death. For MCAD deficiency, we identified 83 outcomes from 52 articles. The most frequently represented core area was pathophysiological manifestations, with 33 outcomes reported in 29/52 articles (56%). Death was the most frequently reported outcome. One-third of outcomes were reported by a single study. The most diversely measured outcome was cognition and intelligence/IQ for which eight unique measurement instruments were reported among 14 articles. For PKU, we identified 97 outcomes from 343 articles. The most frequently represented core area was pathophysiological manifestations with 31 outcomes reported in 281/343 articles (82%). Phenylalanine concentration was the most frequently reported outcome. Sixteen percent of outcomes were reported by a single study. Similar to MCAD deficiency, the most diversely measured PKU outcome was cognition and intelligence/IQ with 39 different instruments reported among 82 articles. Heterogeneity of reported outcomes and outcome measurement instruments across published studies for both MCAD deficiency and PKU highlights the need for COSs for these diseases, to promote the use of meaningful outcomes and facilitate comparisons across studies.